Apoptosis in hepatitis c virus infection

Cell Death and Differentiation

Volumn 10, Issue , 2003, Pages S48-S58

  Bantel, H ^a   Schulze Osthoff, K ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Caspase; Cd95; Cytotoxic t lymphocyte; Hcv; Hepatitis; Heptocellular carcinoma

Indexed keywords

CASPASE; CYTOKINE; FAS ANTIGEN; GRANZYME B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS PROTEIN;

APOPTOSIS; CANCER RISK; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REGULATORY MECHANISM; RETROSPECTIVE STUDY; REVIEW; TRANSGENIC ANIMAL; UPREGULATION; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL TRANSFORMATION, NEOPLASTIC; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

ANIMALIA; HEPATITIS C VIRUS;

EID: 0037274212     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401119     Document Type: Review

References (127)

1. Alter MJ (1997) Epidemiology of hepatitis C. Hepatology 26: 62S-65S
2. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y and Okita K (1999) Differences in hypervariable region 1 quasispecies ofhepatitisCvirus inhuman serum, peripheral bloodmononuclear cells, and liver. Hepatology 29: 217-222
3. Muratori L, Gibellini D, Lenzi M, Cataleta M, Muratori P, Morelli MC and Bianchi FB (1996) Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood 88: 2768-2774
4. Radkowski M, Kubicka J, Kisiel E, Cianciara J, Nowicki M, Rakela J and Laskus T (2000) Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 95: 3986-3989
5. Agnello V, Abel G, Knight GB and Muchmore E (1998) Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology 28: 573-584
6. Kerr JF (1971) Shrinkage necrosis: a distinct mode of cellular death. J. Pathol. 105: 13-20
7. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA and Nagata S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317
8. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T and Nagata S (1994)Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969-976
9. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809
10. Tanaka M, Suda T, Yatomi T, Nakamura N and Nagata S (1997) Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J. Immunol. 158: 2303-2309
11. Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, Etoh Y, Ikematsu H and Kashiwagi S (1997) Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25: 697-701
12. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, Fusamoto H and Kamada T (1994) Immunohistochemical detection of Fas antigenin liver tissueofpatientswith chronic hepatitisC.Hepatology 19:1354-1359
13. Okazaki M, Hino K, Fujii K, Kobayashi N and Okita K (1996) Hepatic Fas antigen expression before and after interferon therapy in patientswith chronic hepatitis C. Dig. Dis. Sci. 41: 2453-2458
14. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, Fusamoto H and Kamada T (1994) Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem. Biophys. Res. Commun. 204: 468-474
15. Ferenbach DA, Haydon GH, Rae F, Malcomson RD and Harrison DJ (1997) Alteration in mRNA levels of Fas splice variants in hepatitis C-infected liver. J. Pathol. 183: 299-304
16. Pianko S, Patella S, Ostapowicz G, Desmond P and Sievert W (2001) Fasmediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J. Viral Hepat. 8: 406-413
17. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A and Hori M (1998) Serum levels of soluble Fas antigen in chronic hepatitis C patients. J. Hepatol. 29: 517-523
18. Nelson DR, Marousis CG, Davis GL, Rice CM, WongJ, Houghton M and Lau JY (1997) The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol. 158: 1473-1481
19. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL and Walker CM (2001) The outcome of hepatitisCvirus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15: 883-895
20. Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P and Walker BD (2000) Analysis of successful immuneresponses in persons infected with hepatitis C virus. J.Exp. Med. 191: 1499-1512
21. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC and Chisari FV (2001) Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194: 1395-1406
22. McGuinness PH, Bishop GA, Painter DM, Chan R and McCaughan GW(1996) Intrahepatic hepatitis CRNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 23: 676-687
23. Rodriguez-Inigo E, Bartolome J, de Lucas S, Manzarbeitia F, Pardo M, Arocena C, Gosalvez J, Oliva H and Carreno V (1999) Histological damage in chronic hepatitisCis not related to the extent of infection in the liver.Am. J. Pathol. 154: 1877-1881
24. Calabrese F, Pontisso P, Pettenazzo E, Benvegnu L, Vario A, Chemello L, Alberti A and Valente M (2000) Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 31: 1153-1159
25. Nuti S, Rosa D, Valiante NM, Saletti G, Caratozzolo M, Dellabona P, Barnaba V and Abrignani S (1998) Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Valpha24+ T cells and rapid elimination of effector cells by apoptosis. Eur. J. Immunol. 28: 3448-3455
26. Muschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R and Haussinger D (1999) Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation. Gastroenterology 116: 666-677
27. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S and Suda T (1998) Caspase 1- independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4: 1287-1292
28. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Moreno-Otero R, Alonso JL, Yague E, Pivel JP, Lopez-Cabrera M, Fernandez-Ruiz E and Sanchez-Madrid F (1994) Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J. Exp. Med. 179: 841-848
29. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, Yagita H, Okumura K and Imawari M (1997) Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virusspecific human CTL. J. Immunol. 158: 5283-5291
30. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M and Walker BD (1995) HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J. Clin. Invest. 96: 2311-2321
31. Tokushige K, Yamaguchi N, Ikeda I, Hashimoto E, Yamauchi K and Hayashi N (2000) Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am. J. Gastroenterol. 95: 2040-2046
32. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG and Wendel A (1995) Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol. 146: 1220-1234
33. Jaeschke H, Fisher MA, Lawson JA, Simmons CA, Farhood A and Jones DA (1998) Activation of caspase 3 (CPP32)-like proteases is essential for TNFalpha- induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 160: 3480-3486
34. Gantner F, Leist M, Lohse AW, Germann PG and Tiegs G (1995) Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21: 190-198
35. Kunstle G, Hentze H, Germann PG, Tiegs G, Meergans T and Wendel A (1999) Concanavalin A hepatotoxicity in mice: tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology 30: 1241-1251
36. Sedger LM, Shows DM, Blanton RA, Peschon JJ, Goodwin RG, Cosman D and Wiley SR (1999) IFN-gamma mediates a novel antiviral activity through dynamicmodulation of TRAIL and TRAIL receptor expression. J. Immunol. 163: 920-926
37. Strater J, Walczak H, Pukrop T, Von Muller L, Hasel C, Kornmann M, Mertens T and Moller P(2002) TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 122: 659-666
38. Zhang M, Li X, Pang X, Ding L, Clouse K, Hewlett I and Dayton AI (2001) Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of TRAIL in primary human macrophages by HIV-1 TAT. J. Biomed. Sci. 8: 291-296
39. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, Yagita H, Okumura K, Tanaka N, Taniguchi T and Ogasawara K (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol. 31: 3138-3146
40. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR and Fanger NA (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factorrelated cytokine, TRAIL. J. Exp. Med. 189: 1343-1354
41. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K and Yagita H (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189: 1451-1460
42. Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H and Schonrich G (2001) Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15: 995-1009
43. Shin EC, Ahn JM, Kim CH, Choi Y, Ahn YS, Kim H, Kim SJ and Park JH (2001) IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int. J. Cancer 93: 262-268
44. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163
45. Jo M, H. KT, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factorrelated apoptosis-inducing ligand. Nat. Med. 6: 564-567
46. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D and Ashkenazi A (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7: 383-385
47. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP and Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7: 954-960
48. Chandler JM, Cohen GM and MacFarlane M (1998) Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver. J. Biol. Chem. 273: 10815-10818
49. Van Molle W, Denecker G, Rodriguez I, Brouckaert P, Vandenabeele P and Libert C (1999) Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. J. Immunol. 163: 5235-5241
50. Kunstle G, Leist M, Uhlig S, Revesz L, Feifel R, MacKenzie A and Wendel A (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Immunol Lett. 55: 5-10
51. Rouquet N, Pages JC, Molina T, Briand P and Joulin V (1996) ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr. Biol. 6: 1192-1195
52. Bantel H, Ruck P, Gregor M and Schulze-Osthoff K (2001) Detectionof elevated caspase activation and early apoptosis in liver diseases. Eur. J. Cell Biol. 80: 230-239
53. Bantel H, Ruck P and Schulze-Osthoff K (2000) In situ monitoring of caspase activation in hepatobiliary diseases. Cell Death Differ. 7: 504-505
54. Bantel H, Lugering A, Poremba C, Lugering N, Held J, Domschke W and Schulze-Osthoff K (2001) Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 34: 758-767
55. Kronenberger B, Ruster B, Lee JH, Sarrazin C, Roth WK, Herrmann G and Zeuzem S (2000) Hepatocellular proliferation in patients with chronic hepatitis Cand persistently normal or abnormal aminotransferase levels. J.Hepatol. 33: 640-647
56. Schulze-Osthoff K, Walczak H, Droge W and Krammer PH (1994) Cell nucleus and DNA fragmentation are not required for apoptosis. J. Cell Biol. 127: 15-20
57. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W and Schulte-Hermann R (1995) In situ detection of fragmentedDNA(TUNELassay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21: 1465-1468
58. Lawson JA, Fisher MA, Simmons CA, Farhood A and Jaeschke H (1998) Parenchymal cell apoptosis as a signal for sinusoidal sequestration and transendothelial migration of neutrophils in murine models of endotoxin and Fas-antibody-induced liver injury. Hepatology 28: 761-767
59. Faouzi S, Burckhardt BE, Hanson JC, Campe CB, Schrum LW and Maher JJ (2001) Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J. Biol. Chem. 276: 4977-4982
60. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ and Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107
61. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, TeuberGand RothWK(1998) Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 28: 245-252
62. Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E and Balart L (1997) Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am. J. Gastroenterol. 92: 1788-1792
63. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME (1998) Apoptosis signaling by death receptors. Eur. J. Biochem. 254: 439-459
64. Rodriguez I, Matsuura K, Ody C, Nagata S and Vassalli P (1996) Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med. 184: 2067-2072
65. Jones RA, Johnson VL, Buck NR, Dobrota M, Hinton RH, Chow SC and Kass GE (1998) Fas-mediated apoptosis in mouse hepatocytes involves the processing and activation of caspases. Hepatology 27: 1632-1642
66. Medema JP, Toes RE, Scaffidi C, Zheng TS, Flavell RA, Melief CJ, Peter ME, Offringa R and Krammer PH (1997) Cleavage of FLICE (caspase-8) by granzymeBduring cytotoxicTlymphocyte-induced apoptosis.Eur. J. Immunol. 27: 3492-3498
67. Sarin A, Haddad EK and Henkart PA (1998) Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J. Immunol. 161: 2810-2816
68. Lacronique V, Mignon A, Fabre M, Viollet B, Rouquet N, Molina T, Porteu A, Henrion A, Bouscary D, Varlet P, Joulin V and Kahn A (1996) Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2: 80-86
69. Feldmann G, Haouzi D, Moreau A, Durand-Schneider AM, Bringuier A, Berson A, Mansouri A, Fau D and Pessayre D (2000) Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology 31: 674-683
70. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA and Korsmeyer SJ (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400: 886-891
71. Dai C and Krantz SB (1999) Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 93: 3309-3316
72. Chin YE, Kitagawa M, Kuida K, Flavell RA and Fu XY (1997) Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell Biol. 17: 5328-5337
73. Fulda S and Debatin KM (2002) IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295-2308
74. Kumar A, Commane M, Flickinger TW, Horvath CM and Stark GR (1997) Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278: 1630-1632
75. Wang Y, Wu TR, Welte T and Chin YE (2000) Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NFkappaB activation. Mol. Cell Biol. 20: 405-412
76. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR and Barber GN (2000) Essential role for the ds RNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 13: 129-141
77. Gale Jr MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR and Katze MG (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230: 217-227
78. Barber GN (2001) Host defense, viruses and apoptosis. Cell Death Differ. 8: 113-126
79. Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S and Schulze-Osthoff K (1998) Role of reactive oxygen intermediates in activation-inducedCD95(APO-1/Fas) ligand expression. J. Biol. Chem. 273: 8048-8055
80. Chan H, Bartos DP and Owen-Schaub LB (1999) Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappa B p50- p65 recruitment. Mol. Cell Biol. 19: 2098-2108
81. Kuhnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M and Kubicka S (2000) NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275: 6421-6427
82. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K and Barber GN (1998) Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 17: 6888-6902
83. DeFrancesco R (1999) Molecular virology of the hepatitisCvirus. J.Hepatol.31 (Suppl. 1): 47-53
84. Ray RB, Meyer K and Ray R (1996) Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226: 176-182
85. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB and Ray R (1998) Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J. Biol. Chem. 273: 2256-2259
86. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC and Lemon SM (2000) Hepatitis Cvirus core protein induces apoptosis and impairs cell-cycle regulation in stably transformedChinese hamster ovary cells. Hepatology 31: 1351-1359
87. Dumoulin FL, von dem Bussche A, Sohne J, Sauerbruch T and Spengler U (1999) Hepatitis C virus core protein does not inhibit apoptosis in human hepatoma cells. Eur. J. Clin. Invest. 29: 940-946
88. Marusawa H, Hijikata M, Chiba T and Shimotohno K (1999) Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J. Virol. 73: 4713-4720
89. Ruggieri A, Harada T, Matsuura Y and Miyamura T (1997) Sensitization to Fasmediated apoptosis by hepatitis C virus core protein. Virology 229: 68-76
90. Hahn CS, Cho YG, Khan BS, Lester IM and Hahn YS (2000) The HCV core protein acts as a positive regulator of Fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology 266: 127-137
91. Zhu N, Khoshnan A, Schneider R, Matsumoto M, Dennert G, Ware C and Lai MM (1998) Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF)receptor1andenhancesTNF-inducedapoptosis. J.Virol. 72: 3691-3697
92. Zhu N, Ware CF and Lai MM (2001) Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology 283: 178-187
93. Lu W, Lo SY, Chen M, Wu K, Fung YK and Ou JH (1999) Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology 264: 134-141
94. Ray RB, Steele R, Meyer K and Ray R (1998) Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. Gene 208: 331-336
95. Otsuka M, Kato N, Lan K, Yoshida H, Kato J, Goto T, Shiratori Y and Omata M (2000) Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. J. Biol. Chem. 275: 34122-34130
96. Okuda M, Li K, Beard MR, Showalter LA, Scholle F and Weinman SA (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122: 369-375
97. Fujita T, Ishido S, Muramatsu S, Itoh M and Hotta H (1996) Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. Biochem. Biophys. Res. Commun. 229: 825-831
98. Gosh A (2000) Hepatitis C Virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res. 67: 173-178
99. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F and Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334: 77-81
100. Honda A, Hatano M, Kohara M, Arai Y, Hartatik T, Moriyama T, Imawari M, Koike K, Yokosuka O, Shimotohno K and Tokuhisa T (2000) HCV-core protein accelerates recovery from the insensitivity of liver cells to Fas-mediated apoptosis induced by an injection of anti-Fas antibody in mice. J. Hepatol. 33: 440-447
101. Machida K, Tsukiyama-Kohara K, Seike E, Tone S, Shibasaki F, Shimizu M, Takahashi H, Hayashi Y, Funata N, Taya C, Yonekawa H and Kohara M (2001) Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J. Biol. Chem. 276: 12140-12146
102. Chisari FV (1997) Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99: 1472-1477
103. Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM and Chisari FV (1996) Differential cytotoxic T-lymphocyte responsiveness to the hepatitisBandCviruses in chronically infected patients. J. Virol. 70: 7092-7102
104. Hiroishi K, Kita H, Kojima M, Okamoto H, Moriyama T, Kaneko T, Ishikawa T, Ohnishi S, Aikawa T, Tanaka N, Yazaki Y, Mitamura K and Imawari M (1997) Cytotoxic T lymphocyte response and viral load in hepatitis C virus infection. Hepatology 25: 705-712
105. Piazzolla G, Tortorella C, Fiore G, Serrone M, Caccetta L, Jirillo E, Schiraldi O and Antonaci S (1998) Immunoresponsiveness in chronic hepatitis C patients: correlation between tissue and serum findings. Immunopharmacol. Immunotoxicol. 20: 337-354
106. Yao ZQ, Nguyen DT, Hiotellis AI and Hahn YS (2001) Hepatitis C virus core protein inhibits human lymphocyte responses by a complement-dependent regulatory pathway. J. Immunol. 167: 5264-5272
107. Tseng CTK and Klimpel GR (2002) Binding of the hepatitis C virus envelope proteinE2 toCD81 inhibits natural killer cell functions. J. Exp. Med. 195: 43-49
108. Emi K, Nakamura K, Yuh K, Sugyo S, Shijo H, Kuroki M and Tamura K (1999) Magnitude of activity in chronic hepatitis C is influenced by apoptosis of T cells responsible for hepatitis C virus. J. Gastroenterol. Hepatol. 14: 1018-1024
109. Nakamoto Y, Kaneako S and Kobayashi K (2001) Monocyte-dependent cell death of T lymphocyte subsets in chronic hepatitis C. Immunol. Lett. 78: 167-174
110. Toubi E, Kessel A, Goldstein L, Slobodin G, Sabo E, Shmuel Z and Zuckerman E (2001) Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J. Hepatol. 35: 774-780
111. Taya N, Torimoto Y, Shindo M, Hirai K, Hasebe C and Kohgo Y (2000) Fasmediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br. J. Haematol. 110: 89-97
112. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH and Lenardo MJ (1995) Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351
113. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH and Runkel L (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182: 1223-1230
114. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T and Koike K (1998) Thecoreprotein of hepatitisCvirus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4: 1065-1067
115. Lerat H, Honda M, Beard MR, Loesch K, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA and Lemon SM (2002) Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122: 342-365Higaki K, Yano H and Kojiro M (1996) Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am. J. Pathol. 149: 429-432
116. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2: 1361-1366
117. Kato N, Yoshida H, Kioko Ono-Nita S, Kato J, Goto T, Otsuka M, Lan K, Matsushima K, Shiratori Y and Omata M (2000) Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 32: 405-412
118. Heim MH, Moradpour D and Blum HE (1999) Expression of hepatitis C virus proteins inhibits signal transduction throughthe Jak-STATpathway. J.Virol.73: 8469-8475
119. Shrivastava A, Manna SK, Ray R and Aggarwal BB (1998) Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J. Virol. 72: 9722-9728
120. Boya P, Larrea E, Sola I, Majano PL, Jimenez C, Civeira MP and Prieto J (2001) Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression. Hepatology 34: 1041-1048
121. Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NFkappa B. Nature 376: 167-170
122. Yamada Y, Kirillova I, Peschon JJ and Fausto N (1997) Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl. Acad. Sci. USA 94: 1441-1446
123. Frommel TO, Yong S and Zarling EJ (1999) Immunohistochemical evaluationof Bcl-2 gene family expression in liver of hepatitisCand cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Am. J. Gastroenterol. 94: 178-182
124. Yanagi M, Purcell RH, Emerson SU and Bukh J (1997) Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver ofachimpanzee. Proc.Natl. Acad.Sci.USA 94:8738-8743
125. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM and Rice CM (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277: 570-574
126. Lohmann V, Korner F, Koch J, Herian U, Theilmann L and Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113
127. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL and Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7: 925-933